Navigation Links
Pharmasset Reports Fiscal First Quarter 2011 Financial Results
Date:2/7/2011

PRINCETON, N.J., Feb. 7, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS), a clinical stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections, today reported financial results and operational highlights for the quarter ended December 31, 2010.

Financial ResultsRevenues were $0.2 million during the quarter ended December 31, 2010 compared to $0.3 million for the quarter ended December 31, 2009 and include amortization of up-front and subsequent collaborative and license payments received from Roche.

Net cash used in operating activities during the three months ended December 31, 2010 was $24.0 million. Pharmasset held $102.7 million in cash and cash equivalents as of December 31, 2010. On January 26, 2011, we completed a common stock offering raising an additional $123.4 million.

Total operating expenses for the quarter ended December 31, 2010 were $23.8 million as compared to $13.4 million for the same period in 2009. The increase in operating expenses for the quarter ended December 31, 2010 was primarily the result of preclinical and clinical trial costs for PSI-7977 and PSI-938 of which $5.9 million was related to API manufacturing (and related drug supply) costs and pegylated interferon and ribavirin costs for the studies of PSI-7977 and PSI-938.

Pharmasset reported a net loss of $23.5 million, or $0.69 per share, for the quarter ended December 31, 2010, as compared to a net loss of $13.9 million, or $0.49 per share, for the quarter ended December 31, 2009.

Recent Operational Highlights:-- Presented final Phase 2a results with PSI-7977 at the American Association for the Study of Liver Diseases (AASLD) in October 2010

-- Initiated Part 2 of a Phase 1 study that includes combinations of PSI-7977 and PSI-938

-- Roche reported 12 week interim results f
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
10. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
11. Pharmasset Receives Notice of Allowance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 21, 2014  Seventy-one percent of Americans believe the abuse ... serious public health and safety issue in the ... released today by Repass & Partners, a Cincinnati ... understand the severity of the prescription medication abuse problem and ... very serious health situation facing our country," Rex Repass ...
(Date:8/21/2014)... 21, 2014 BreedIT Corp., ... the exclusive worldwide license holder and distributor of ... and researchers, today is pleased to announce the ... Seach Ltd, a leading Israeli medical Cannabis breeder. ... develop new breeds of medical Cannabis to meet ...
(Date:8/21/2014)...  Henry Schein, Inc. (NASDAQ: HSIC ), the ... office-based dental, animal health and medical practitioners, announced today that ... , September 4, 2014 – Baird 2014 Healthcare ... p.m. ET , September 8, 2014 – ... , NY at 1:25 p.m. ET Henry ...
Breaking Medicine Technology:Consumers Desperate For Measures To Curb Prescription Drug Abuse 2Consumers Desperate For Measures To Curb Prescription Drug Abuse 3BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 2BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 3BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 4Henry Schein To Present At Two Investor Conferences In September 2
... April 20, 2012  Adam Levine, lead singer of Maroon ... Own It Project." "The Own It Project" is designed ... responsibility for their Attention-Deficit/Hyperactivity Disorder (ADHD) – and owning ... by entering their story for a chance to become ...
... WOONSOCKET, R.I., April 20, 2012  CVS Caremark Corporation (NYSE: ... call on Wednesday, May 2, 2012, at 8:30 a.m. ... quarter 2012 financial results. (Logo: http://photos.prnewswire.com/prnh/20090226/NE75914LOGO ... conference call will be broadcast simultaneously through the Investor ...
Cached Medicine Technology:Maroon 5 Lead Singer Adam Levine and Shire Announce "The Own It Project," Encouraging Adults with Attention-Deficit/Hyperactivity Disorder to Tell Their Stories Through a National Contest 2Maroon 5 Lead Singer Adam Levine and Shire Announce "The Own It Project," Encouraging Adults with Attention-Deficit/Hyperactivity Disorder to Tell Their Stories Through a National Contest 3Maroon 5 Lead Singer Adam Levine and Shire Announce "The Own It Project," Encouraging Adults with Attention-Deficit/Hyperactivity Disorder to Tell Their Stories Through a National Contest 4Maroon 5 Lead Singer Adam Levine and Shire Announce "The Own It Project," Encouraging Adults with Attention-Deficit/Hyperactivity Disorder to Tell Their Stories Through a National Contest 5Maroon 5 Lead Singer Adam Levine and Shire Announce "The Own It Project," Encouraging Adults with Attention-Deficit/Hyperactivity Disorder to Tell Their Stories Through a National Contest 6CVS Caremark Corporation to Hold First Quarter 2012 Conference Call 2
(Date:8/22/2014)... August 22, 2014 Testosterone treatment ... in U.S. courts on behalf of men who ... use of prescription low testosterone therapies, Bernstein Liebhard ... claim was filed against Pfizer Inc. on July ... life-threatening heart issues due to his use of ...
(Date:8/22/2014)... August 22, 2014 The improved access ... specifically in the developing world, has led to the ... number of deaths due to AIDS globally. However, despite ... number of new patients becoming affected by the virus ... being undertaken by all related organisations and stakeholders, by ...
(Date:8/22/2014)... Dayton, Ohio (PRWEB) August 22, 2014 Dayton ... patient care tower as part of a $141 million campus ... new patient care tower were unveiled to the public. ... campus facilities plan that will create a campus that meets ... the future. These new care spaces will embody Dayton Children’s ...
(Date:8/22/2014)... 2014 Menstrual leaks risk stains and ... Fla., decided that there needed to be a better ... and producible in design variations, the Safety Net optimizes ... which avoids embarrassment and promotes peace of mind. The ... , The original design was submitted to the Fort ...
(Date:8/22/2014)... News) -- Many children get anxious or afraid when ... a number of ways that parents can make these ... The first step is to explain to children in ... health, said Rita John, director of the pediatric primary ... Nursing in New York City. "Children need to ...
Breaking Medicine News(10 mins):Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 2Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 3Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 4Health News:Worldwide HIV Infection Drug Market Examined in New Kuick Research Report Published at MarketPublishers.com 2Health News:Worldwide HIV Infection Drug Market Examined in New Kuick Research Report Published at MarketPublishers.com 3Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 2Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 3Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 4Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 5Health News:Simple Steps Make Shots Less Scary for Kids, Nurse Says 2
... could ease sickle-cell disease and thalassemia , ... ... Hospital Boston ( www.childrenshospital.org ) and Dana-Farber Cancer Institute have ... a form of hemoglobin normally made only before birth or ...
... Toy Safety Program Offers Manufacturers A Way to Improve Toy ... Improvement Act , , ANN ... generate concerns among consumers about the safety of their children,s ... Safety team offers a solution -- integrated services that include ...
... 4 Omron Healthcare, Inc. reminds,consumers to take full ... (FSA,s) before they expire by purchasing products to take,control ... blood pressure,monitors and nebulizers. , ... (Photo: http://www.newscom.com/cgi-bin/prnh/20081204/AQTH541-b ...
... Nash Corporation (Nasdaq: KNSY ) is scheduled to participate ... 2008 RBC Capital Markets Healthcare Conference. , , ... the panel discussion on Thursday, December 11th at 11:00 a.m. ET ... The conference is by invitation only, however individuals can listen ...
... of vigorous activity a week , , THURSDAY, Dec. 4 ... in the United States last year met the 2008 ... those people met the Healthy People 2010 physical activity ... , According to the 2008 guidelines, released in October ...
... family today unveiled,the details of a successful holiday party held ... possible by Biel,s Make The Difference,Network, included numerous recording artists ... spirit to children at the hospital. , ... well as seeing some of the,great artists we had at ...
Cached Medicine News:Health News:Turning back the Clock in Inherited Anemias 2Health News:Turning back the Clock in Inherited Anemias 3Health News:Turning back the Clock in Inherited Anemias 4Health News:NSF International Offers Answers to Rising Toy Safety Concerns 2Health News:Maximize Flex Spending Account Funds Before They Expire 2Health News:Maximize Flex Spending Account Funds Before They Expire 3Health News:Kensey Nash to Participate in the RBC Capital Markets Healthcare Conference 2Health News:Almost Two-Thirds of Americans Meet Exercise Guidelines 2Health News:Almost Two-Thirds of Americans Meet Exercise Guidelines 3Health News:Jessica Biel and Make The Difference Network Bring Holiday Cheer to Childrens Hospital Los Angeles 2
The Heine C series binocular loupes offer extremely low weight (46 g), crisp views, and quality German construction in an affordable instrument....
C 2.3K with lightweight headband: the practical alternative for spectacle-wearers. Delivered in protective designer case....
Easyloupes are exceptional optics that you have come to expect from Oculus. Available in either 1.8x or 2.5x magnification and 40 cm working distance (15.75 inches), they have the well-known durabili...
... implant is a device that delivers ... Cytomegalovirus (CMV) Retinitis. This approach can ... compared with conventional intravenous treatment. The ... a polymer-based system that slowly releases ...
Medicine Products: